Adjunctive management for high-risk Kawasaki disease
The role of systemic corticosteroids for the first-line management of Kawasaki disease is controversial; seek advice from a specialist. Longer courses of oral corticosteroids (tapering over 2 to 3 weeks), in addition to intravenous immunoglobulin (IVIg) and low-dose aspirin, may be considered for high-risk patients (those with coronary artery lesions); however, use of single-dose pulse intravenous methylprednisolone is not advised.